Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
COVID-19
100%
Platform Trials
100%
Usual Care
100%
Sotrovimab
100%
Antigen Levels
54%
COVID-19 Pneumonia
27%
Safety Outcomes
18%
Treatment Options
9%
High Risk
9%
Between-group
9%
Web-based
9%
Significant Risk Factors
9%
Healthcare Research
9%
Standard of Care
9%
Omicron Variant
9%
Vaccination
9%
Rate Ratio
9%
Medical Research Council
9%
Risk of Death
9%
Adaptive Platform Trial
9%
Intention-to-treat
9%
Antibody Targeting
9%
SARS-CoV-2 Variants
9%
28-day Mortality
9%
Serostatus
9%
UK Hospitals
9%
Reduced Mortality
9%
RECOVERY Trial
9%
Antibody Therapy
9%
Neutralizing Antibodies
9%
National Institute for Health Research
9%
Nucleocapsid Antigen
9%
High-level Resistance
9%
Antigen Concentration
9%
Anti-spike Antibody
9%
Omicron Infection
9%
Infusion Reaction
9%
Neutralizing Monoclonal Antibody
9%
SARS-CoV-2 Antigen
9%
SARS-CoV-2 Spike Protein
9%
Investigator-initiated
9%
Medicine and Dentistry
COVID-19
100%
Severe Acute Respiratory Syndrome Coronavirus 2
80%
Infusion
40%
Omicron Coronavirus Variant
40%
Monoclonal Antibody
20%
Intention-to-Treat Analysis
20%
Antibody Therapy
20%
Neutralizing Antibody
20%
Treatment Option
20%
Primary Outcome
20%
Virus Nucleocapsid
20%
Immunology and Microbiology
COVID-19
100%
Severe Acute Respiratory Syndrome Coronavirus 2
80%
Spike
40%
Omicron Coronavirus Variant
40%
Monoclonal Antibody
20%
Neutralizing Antibody
20%
Virus Nucleocapsid
20%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
100%
Monoclonal Antibody
25%
Neutralizing Antibody
25%